Revolution Medicines starts Phase 3 trial of zoldonrasib for pancreatic cancer

June 23, 2026 8:00 AM

Revolution Medicines has begun enrolling patients in RASolute 305, a global Phase 3 clinical trial evaluating zoldonrasib in combination with ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found